🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

19 results for “brentuximab” Clear

  1. Brentuximab Vedotin

    Takeda

    Primary Cutaneous Anaplastic Large Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  2. Brentuximab Vedotin for Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Classical Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  3. Brentuximab vedotin

    Takeda

    Diffuse Large B-cell-lymphoma

    phase 3 small molecule active

    1 trial

  4. Brentuximab vedotin

    Pfizer

    Diffuse Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  5. brentuximab vedotin

    Takeda

    Hodgkin Lymphoma

    phase 3 small molecule completed

    3 trials

  6. ADCETRIS 50 mg powder for concentrate for solution for infusion

    Takeda

    Hodgkin lymphoma (HL) - Hodgkin lymphoma (HL), a neoplasm of lymphoid tissue which is histopathologically defined by the presence of malignant Hodgkin Reed-Sternberg (HRS) cells in a background of inflammatory cells. The proposed pediatric study has been designed to evaluate brentuximab vedotin as a component of a multiagent frontline chemotherapy regimen in patients with advanced stage, newly diagnosed HL, here defined as Stage III and Stage IV and a ≥50 Lansky Play-Performance or Karnofsky Performance Status.

    phase 2 small molecule active

    1 trial

  7. Brentuximab Vedotin

    United Therapeutics Europe Ltd

    Ann Arbor Stage IB Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  8. Brentuximab Vedotin

    Takeda

    Enteropathy Associated T-cell Lymphoma

    phase 2 small molecule completed

    1 trial

  9. Brentuximab Vedotin

    Takeda

    Hodgkin Disease

    phase 2 small molecule active

    2 trials

  10. Brentuximab Vedotin in Combination with Tislelizumab

    Takeda

    NK/T Cell Lymphoma Nos

    phase 2 small molecule active

    1 trial

  11. Brentuximab vedotin

    Takeda

    Relapsed or Refractory Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  12. BrentuximabVedotin (BV)

    Takeda

    Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  13. Brentuximab Vedotin

    Takeda

    Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic

    phase 1 small molecule terminated

    1 trial

  14. TGR-1202 + brentuximab vedotin

    TG THERAPEUTICS, INC.

    Hodgkin's Lymphoma

    phase 1 small molecule completed

    1 trial

  15. Takeda Brentuximab; Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma

    Disc Medicine

    Patients with stage II-IV high risk diffuse large B-cell lymphoma, defined as international prognostic index > 2, Lymphoma

    phase 1 other active

    1 trial

  16. Brentuximab vedotin

    Takeda

    T-Cell Lymphoma

    approved small molecule completed

    1 trial

  17. Brentuximab vedotin

    Takeda

    Lymphoma

    approved small molecule active

    2 trials

  18. Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)

    Hospital Authority, Hong Kong

    CD30+ Peripheral T-cell Lymphoma

    small molecule active

    1 trial

  19. Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)

    The First People's Hospital of Lianyungang

    CD30+ Peripheral T-cell Lymphoma

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources